

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 49464 Insp GMP/IMP 49464/18321324-0004[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : ENTEROBIOTIX LIMITED

Site address : ENTEROBIOTIX LIMITED, ABERDEEN BLOOD TRANSFUSION CENTRE, FORESTERHILL ROAD, ABERDEEN, AB25 2ZW, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 49464 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 26/07/2022 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.2] Non-sterile investigational medicinal products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.6] Liquids for internal use

[1.2.1.17] Other non-sterile medicinal products

FAECAL MICROBIOTA

[1.2.2] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.6] Human or animal extracted products

[1.3.1.8] Other biological medicinal products

FAECAL MICROBIOTA

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.6] Liquids for internal use

[1.5.1.17] Other non-sterile medicinal products

FAECAL MICROBIOTA

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.1] Microbiological: sterility

Restrictions or Remarks

Secondary packaging of IMPs is approved for open-label studies only and does not involve labelling for blinded studies.

04/10/2022	Name and signature of the authorised person of the Competent Authority of United Kingdom
	Confidential
	Medicines and Healthcare products Regulatory Agency
	Tel : Confidential